Genomics England, AI Startup Collaborate on Immunotherapy

Mar 21, 2019

|

NEW YORK (GenomeWeb) – Genomics England said today that it has enlisted a startup maker of artificial intelligence in a long-term partnership meant to increase patient access to immunotherapies, monitor treatment effectiveness, and identify resistance to these advanced cancer drugs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Mar

23

Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar

30

Featured Webinar

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Apr

08

Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

Menu

Genomics England, AI Startup Collaborate on Immunotherapy

To read the full story....

Breaking News

UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer

Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients

Amgen to Acquire Five Prime Therapeutics for $1.9B

Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

C2i Genomics Acquires Sequencing Lab QNA Dx

FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

What's Popular?

Nonprofit Count Me In to Return Genomic Results to Patients With Rare Cancers

C2i Genomics Acquires Sequencing Lab QNA Dx

Sponsorships